DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models.

about

PFK15, a Small Molecule Inhibitor of PFKFB3, Induces Cell Cycle Arrest, Apoptosis and Inhibits Invasion in Gastric Cancer

P2860

Q28554349-5B50A322-FFA7-4C6C-AE86-CD6AD831DACC

P2860

DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models.

Item

http://www.wikidata.org/entity/Q38803566

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

DCT015, a new sorafenib deriva ...... esis in gastric cancer models.

@en

type

Item

label

DCT015, a new sorafenib deriva ...... esis in gastric cancer models.

@en

prefLabel

DCT015, a new sorafenib deriva ...... esis in gastric cancer models.

@en

P1476

DCT015, a new sorafenib deriva ...... esis in gastric cancer models.

@en

P2093

Hui Wang

http://www.w3.org/2001/XMLSchema#string

Jingwei Tian

http://www.w3.org/2001/XMLSchema#string

Liang Ye

http://www.w3.org/2001/XMLSchema#string

Wenyan Wang

http://www.w3.org/2001/XMLSchema#string

Yingying Ni

http://www.w3.org/2001/XMLSchema#string

Zhenming Yao

http://www.w3.org/2001/XMLSchema#string

P2860

Overexpression of brachyury contributes to tumor metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin

Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy

Targeted therapy in gastric cancer: personalizing cancer treatment based on patient genome

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

Targeting the phosphoinositide 3-kinase pathway in cancer

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.

P2888

s13277-016-4826-3

P304

9221-9232

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S13277-016-4826-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1033017068

http://www.w3.org/2001/XMLSchema#string

P698

26768619

http://www.w3.org/2001/XMLSchema#string

DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models.

about

P2860

P2860

DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698